Teva Pharmaceuticals, a U.S. affiliate of Teva, announced the print publication of the IMPACT-TD Scale, a standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia, or TD, on different aspects of a patient’s daily functioning. IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational. The scale was developed to collect insights from not only patients but also family members, caregivers and providers, to help foster more productive dialogue and provide the most comprehensive understanding of the impact of TD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Teva announces FDA approval of AUSTEDO XR tablets
- Teva Neuroscience granted FDA approval for amended Austedo XR NDA
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA
- Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva
- Teva settles price-fixing claims in Florida for $6.73M